Phase 3 N=175 Colorectal Cancer Metastatic
Colorectal Cancer Metastatic
Primary: Percentage of Participants With Adverse Events (AEs) — 100.00; 40.6; 21.1; 9.1 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=29 Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
Phase 2 N=13 Genistein in Treatment of Metastatic Colorectal Cancer
Colon Cancer · Rectal Cancer · Colorectal Cancer
Primary: Number of Adverse Events — 250; 119; 24; 0 events
Phase 1 N=82 MEK and MET Inhibition in Colorectal Cancer
Solid Tumor · Colorectal Cancer
Primary: Maximal Tolerated Dose (MTD) of PD-0325901 and PF-02341066 /PF-02341066 or Binimetinib With PF-02341066 — 0; 0; 0; 1 Dose Limiting Toxicities (DLTs)
Phase 2 N=27 Regorafenib in Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 3 N=760 Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Phase 2 N=83 Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 53.2 percentage of participants
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=62 A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Overall Survival — 8.6; 4.7 months
Phase 2 N=7 New Individualized Therapy Trial for Metastatic Colorectal Cancer
Colorectal Neoplasm · Colorectal Cancer
Primary: Number of Patients With Adverse Events — 5; 0 Participants
Phase 2 N=76 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 2 N=17 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Cancer
Primary: Progression-free Survival (PFS) — 55 Days
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=75 Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Colon Cancer · Colorectal Cancer
Primary: Maximum Tolerated Dose (MTD) of Celebrex in Combination With EPO906 — 9 mg/m2
Phase 2 N=38 Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression-free Survival — 424 days
Phase 2 N=50 Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 63; 42 percentage of participants with response
Phase 2 N=44 Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
Colorectal Cancer
Primary: 12-Week Progression Free Survival — 18 Participants
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=20 Cellular Immune Augmentation in Colon and Rectal Cancer
Colon Cancer · Rectal Cancer
Primary: Participants Exhibiting Immune Response — 11 Participants
Phase 2 N=21 MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Phase 2 N=19 Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
Recurrent Colon Cancer · Recurrent Rectal Cancer · Stage IV Colon Cancer
Primary: Progression-free Survival Rate — 5.3 percentage of participants
Phase 2 N=53 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities — 0 participants
Phase 2 N=50 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus
Colorectal Adenocarcinoma
Primary: Overall Response — 0 percentage of participants
Phase 2 N=44 Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Recurrent Colorectal Carcinoma · Stage IVA Colorectal Cancer · Stage IVB Colorectal Cancer
Primary: To Examine the Adverse Event Profile — 21; 20; 17; 16 participants
Phase 2 N=133 Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Carcinoma · Recurrent Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Progression Free Survival (PFS) — 4.37; 3.32 months — p=0.051